A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer

• Published in: EBioMedicine Vol. 2; no. 1; pp. 82 - 90
• Main Authors: Krishna, Sanjeev, Ganapathi, Senthil, Ster, Irina Chis, Saeed, Mohamed E.M., Cowan, Matt, Finlayson, Caroline, Kovacsevics, Hajnalka, Jansen, Herwig, Kremsner, Peter G., Efferth, Thomas, Kumar, Devinder
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.01.2015; Elsevier
• Subjects: Administration, Oral; Aged; Artemisinins - administration & dosage; Artemisinins - adverse effects; Artemisinins - therapeutic use; Artesunate; Biomarkers, Tumor - metabolism; Carcinoembryonic Antigen - metabolism; Colorectal cancer; Colorectal Neoplasms - drug therapy; Demography; Dihydroartemisinin; Double-Blind Method; Female; Humans; Immunohistochemistry; Ki-67 Antigen - metabolism; Ki67; Male; Neutropaenia; Original; Pilot Projects; Placebos; Staining and Labeling; Survival Analysis; Treatment Outcome; Dihydroartemisinin; Neutropaenia; Ki67; Artesunate; Colorectal cancer

Artesunate is an antimalarial agent with broad anti-cancer activity in in vitro and animal experiments and case reports. Artesunate has not been studied in rigorous clinical trials for anticancer effects. To determine the anticancer effect and tolerability of oral artesunate in colorectal cancer (CR...